Literature DB >> 5127392

C1 inactivator protein complexed with albumin in plasma from a patient with angioneurotic edema.

A B Laurell, U Mårtensson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5127392     DOI： 10.1002/eji.1830010215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


× No keyword cloud information.
  11 in total

1.  Proteinase inhibitors in rheumatoid arthritis.

Authors:  D Brackertz; J Hagmann; F Kueppers
Journal:  Ann Rheum Dis       Date:  1975-06       Impact factor: 19.103

2.  Conversion of the fourth complement component studied by crossed immunoelectrophoresis.

Authors:  A G Sjöholm; A B Laurell
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

Review 3.  The C1 esterase inhibitor and hereditary angioedema.

Authors:  M M Frank
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

4.  Possible therapy in hereditary angioneurotic edema (HAE).

Authors:  D Brackertz; F Kueppers
Journal:  Klin Wochenschr       Date:  1973-06-15

5.  Inherited high serum levels of a functionally deficient complement esterase inhibitor associated with hereditary angioedema.

Authors:  F Kueppers; U Berendes; E Schöpf
Journal:  Humangenetik       Date:  1972

6.  Rapid and sensitive techniques for identification and analysis of 'reactive-centre' mutants of C1-inhibitor proteins contained in type II hereditary angio-oedema plasmas.

Authors:  K S Aulak; R S Harrison
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

7.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.

Authors:  Pilar Sánchez-Corral; David Pérez-Caballero; Olatz Huarte; Ari M Simckes; Elena Goicoechea; Margarita López-Trascasa; Santiago Rodríguez de Córdoba
Journal:  Am J Hum Genet       Date:  2002-11-06       Impact factor: 11.025

8.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M M Frank
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

9.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

10.  Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.

Authors:  K S Aulak; P A Pemberton; F S Rosen; R W Carrell; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.